FDAnews
www.fdanews.com/articles/142349-shire-phase-ii-study-of-mdd-adjunctive-therapy-vyvanse-capsules-meets-endpoints

Shire Phase II Study of MDD Adjunctive Therapy Vyvanse Capsules Meets Endpoints

December 8, 2011
Shire reported results from a Phase II trial of its adjunctive therapy Vyvanse capsules for patients suffering from major depressive disorder with the change in global executive composite T-score of the behavioral rating inventory of executive function - adult version assessment being the primary efficacy measure.
RTT News